Free Trial

Evotec SE (NASDAQ:EVO) Sees Significant Decrease in Short Interest

Evotec logo with Medical background

Evotec SE (NASDAQ:EVO - Get Free Report) was the recipient of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 220,100 shares, a drop of 10.7% from the October 15th total of 246,500 shares. Based on an average daily trading volume, of 138,900 shares, the short-interest ratio is currently 1.6 days. Approximately 0.1% of the shares of the stock are short sold.

Institutional Trading of Evotec

Several institutional investors have recently made changes to their positions in the stock. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Evotec during the second quarter worth approximately $87,000. Cetera Advisors LLC bought a new position in Evotec during the first quarter valued at approximately $188,000. Clear Harbor Asset Management LLC bought a new position in Evotec during the third quarter valued at approximately $104,000. DCF Advisers LLC raised its position in Evotec by 140.5% during the second quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock valued at $552,000 after acquiring an additional 67,156 shares in the last quarter. Finally, Mediolanum International Funds Ltd bought a new position in Evotec during the third quarter valued at approximately $512,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

Evotec Stock Performance

Shares of EVO traded up $0.34 during midday trading on Friday, hitting $5.44. The stock had a trading volume of 1,160,733 shares, compared to its average volume of 309,637. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09. The business has a 50-day simple moving average of $3.66 and a two-hundred day simple moving average of $4.19. Evotec has a fifty-two week low of $2.85 and a fifty-two week high of $12.00.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Morgan Stanley lowered shares of Evotec from an "overweight" rating to an "equal weight" rating and reduced their price objective for the company from $15.00 to $6.00 in a research report on Monday, July 29th. Deutsche Bank Aktiengesellschaft cut shares of Evotec from a "hold" rating to a "sell" rating in a report on Thursday, August 8th. Jefferies Financial Group cut shares of Evotec from a "buy" rating to a "hold" rating and decreased their target price for the stock from $8.70 to $3.80 in a report on Monday, October 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $8.00 target price on shares of Evotec in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $5.93.

Get Our Latest Research Report on EVO

Evotec Company Profile

(Get Free Report)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Evotec right now?

Before you consider Evotec, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.

While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again
Palantir and the NASDAQ 100: What’s the Next Big Stock Swing for This AI Giant?
Rocket Lab Stock Explodes Higher—What’s Next for This Space Pioneer?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines